Section of Nephrology, Dept. of Medicine, The Univ. of Chicago, 5841 S. Maryland Ave., MC5100, Chicago, IL 60637, USA.
Am J Physiol Cell Physiol. 2012 Jan 1;302(1):C46-58. doi: 10.1152/ajpcell.00075.2011. Epub 2011 Sep 28.
Urolithiasis remains a very common disease in Western countries. Seventy to eighty percent of kidney stones are composed of calcium oxalate, and minor changes in urinary oxalate affect stone risk. Intestinal oxalate secretion mediated by anion exchanger SLC26A6 plays a major constitutive role in limiting net absorption of ingested oxalate, thereby preventing hyperoxaluria and calcium oxalate urolithiasis. Using the relatively selective PKC-δ inhibitor rottlerin, we had previously found that PKC-δ activation inhibits Slc26a6 activity in mouse duodenal tissue. To identify a model system to study physiologic agonists upstream of PKC-δ, we characterized the human intestinal cell line T84. Knockdown studies demonstrated that endogenous SLC26A6 mediates most of the oxalate transport by T84 cells. Cholinergic stimulation with carbachol modulates intestinal ion transport through signaling pathways including PKC activation. We therefore examined whether carbachol affects oxalate transport in T84 cells. We found that carbachol significantly inhibited oxalate transport by T84 cells, an effect blocked by rottlerin. Carbachol also led to significant translocation of PKC-δ from the cytosol to the membrane of T84 cells. Using pharmacological inhibitors, we observed that carbachol inhibits oxalate transport through the M(3) muscarinic receptor and phospholipase C. Utilizing the Src inhibitor PP2 and phosphorylation studies, we found that the observed regulation downstream of PKC-δ is partially mediated by c-Src. Biotinylation studies revealed that carbachol inhibits oxalate transport by reducing SLC26A6 surface expression. We conclude that carbachol negatively regulates oxalate transport by reducing SLC26A6 surface expression in T84 cells through signaling pathways including the M(3) muscarinic receptor, phospholipase C, PKC-δ, and c-Src.
尿石症仍然是西方国家非常常见的疾病。70%至 80%的肾结石由草酸钙组成,尿液中草酸的微小变化会影响结石风险。阴离子交换器 SLC26A6 介导的肠道草酸分泌在限制摄入草酸的净吸收方面起着主要的组成作用,从而防止高草酸尿症和草酸钙尿石症。我们之前使用相对选择性的 PKC-δ 抑制剂 rottlerin 发现,PKC-δ 的激活抑制了小鼠十二指肠组织中 Slc26a6 的活性。为了确定研究 PKC-δ 上游生理激动剂的模型系统,我们对人肠细胞系 T84 进行了特征描述。敲低研究表明,内源性 SLC26A6 介导 T84 细胞中大部分的草酸转运。乙酰胆碱刺激通过包括 PKC 激活在内的信号通路调节肠道离子转运。因此,我们研究了 carbachol 是否影响 T84 细胞中的草酸转运。我们发现,carbachol 显著抑制了 T84 细胞的草酸转运,rottlerin 可阻断此作用。carbachol 还导致 PKC-δ 从 T84 细胞的细胞质向膜的显著易位。使用药理学抑制剂,我们观察到 carbachol 通过 M(3)毒蕈碱受体和磷脂酶 C 抑制草酸转运。利用 Src 抑制剂 PP2 和磷酸化研究,我们发现观察到的 PKC-δ 下游调节部分由 c-Src 介导。生物素化研究表明,carbachol 通过减少 SLC26A6 的表面表达来抑制草酸转运。我们得出结论,carbachol 通过包括 M(3)毒蕈碱受体、磷脂酶 C、PKC-δ 和 c-Src 在内的信号通路,通过减少 SLC26A6 的表面表达,负调节 T84 细胞中的草酸转运。